Quoin Pharma (QNRX) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Public company logo of quoinpharma.com (QNRX)

Quoin Pharmaceuticals is establishing strategic alliances with specialized funds to combat hereditary dermatoses, including Netherton syndrome. The unique therapeutic environment they have created ensures full patient loyalty and a seven-year FDA monopoly. The development of proprietary topical agents is based on extensive R&D research into small molecules. This chart of the current share price reflects an EV/EBITDA ratio of 0.00.

Quoin Pharmaceuticals Ltd - QNRX Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/15/2026)

Analytical breakdowns and data insights for company Quoin Pharma (QNRX)

- market price and analyst price targets:
Fundamental company analysis:QNRX (Quoin Pharma)
Original product of Quoin Pharmaceuticals Ltd

EV/EBITDA determines the business value including debt relative to operating profit, allowing for an assessment of the asset's real price without the influence of the tax regime. For Quoin Pharmaceuticals (QNRX), this ratio reflects the capitalization of unique patents in rare skin disease therapy and the dependence of clinics on their supplies. Analyzing the historical EV/EBITDA trajectory helps identify stock overvaluation when market optimism outpaces actual earnings growth.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization krystalbio.com KRYS|Total Company Value to Operating Income Before Depreciation Ratio apogeetherapeutics.com (APGE)|ARQT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VCEL - EV/EBITDA Multiple|ORKA: EV/EBITDA Multiple|SMTI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DBV Technologies|Enterprise Value to Operating Income Before Depreciation SLSN (solesence.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Journey Medical (DERM)|FBRX: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Empro Corporation EMPG|Sol-Gel Technologies, Ltd. (SLGL) - Company Value to EBITDA|AXIL Brands Inc - EV/EBITDA Multiple|MDCX (Medicus Pharma Ltd.) - Enterprise Value to Operating Income Before Depreciation|Verrica (VRCA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Hoth Therapeutics, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization biofrontera-us.com|VYNE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SNOA|EV/EBITDA Multiple Azitra (AZTR)|EV/EBITDA Multiple DRMA (dermatarx.com)|Business Value to Operating Income Before Depreciation ELAB|RVNC: Enterprise Value to EBITDA Ratio